Neurogenic progression may falter in MDD
Postmortem multiomic analyses showed more quiescent neural stem cells and fewer neuroblasts, alongside broader hippocampal molecular changes.
By
Andrea Surnit
August 26, 2026
Clinical Scorecard: Neurogenic progression may falter in MDD
At a Glance
Category Detail
Condition Major Depressive Disorder (MDD) Key Mechanisms Disrupted adult hippocampal neurogenesis and stalled progression from neural stem-like cells to neuroblasts. Target Population Patients with major depressive disorder without recent psychotropic medication use. Care Setting Postmortem analysis of hippocampal tissue.
Key Highlights
Patients with MDD showed impaired neurogenic progression. Fewer neuroblasts and more quiescent neural stem cells were observed in MDD patients. Molecular alterations included increased expression of interferon-related genes and SOX9 in intermediate neural progenitors. Proteomic profiling identified 297 differentially expressed proteins in MDD. Changes extended beyond neurogenic populations affecting neurotransmission and neuroinflammation. Guideline-Based Recommendations
Diagnosis
Postmortem analysis of hippocampal tissue to assess neurogenic changes. Management
Consideration of molecular alterations in neurogenic progression when treating MDD. Monitoring & Follow-up
Assessment of neurogenic lineage progression in patients with MDD. Risks
Limitations in distinguishing MDD-related pathology from suicide-related pathology. Patient & Prescribing Data
Patients with MDD without comorbid substance or alcohol use disorders.
No psychotropic medication use within 3 months prior to death except benzodiazepines.
Clinical Best Practices
Utilize multiomic analyses to understand neurogenic progression in MDD. Monitor for molecular alterations in hippocampal circuitry in MDD patients. Related Resources & Content
